# US 12,224,049 B2 · Systems and methods for monitoring and managing neurological diseases and conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,224,049 B2
- Document ID: US12224049B2
- Status: Granted
- Kind: B2
- Application number: 17/643,363
- Filed: 2021-12-08
- Published: 2022-06-09
- Granted: 2025-02-11
- Earliest claimed: 2020-12-09
- Assignees: Eysz, Inc.
- Applicants: Eysz, Inc.
- Inventors: Rachel Kuperman; Parth Amin; Bikramjit Sarkar
- Web page: https://patentgrep.com/patent/US12224049B2

## CPC

- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 40/63: for local operation
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

Systems and methods for monitoring and managing neurological diseases and conditions are disclosed herein. In some embodiments, a method for monitoring a patient having a neurological disease or condition includes receiving, from one or more patient monitoring devices, first patient data for a baseline time period. The method can include determining, based on the first patient data, first seizure data and first side effect data during the baseline time period. The method can further include receiving, from the one or more patient monitoring devices, second patient data for a treatment time period, and determining, based on the second patient data, second seizure data and second side effect data during the treatment time period. The method can also include generating a personalized dose-response profile for the patient based on the first and second seizure data and the first and second side effect data.

## Claims

### Claim 1

A computer-implemented method for monitoring a patient having a neurological disease or condition, the method comprising:
receiving, from one or more patient monitoring devices configured to produce eye movement data, first patient data for a baseline time period before the patient has started taking medication for the neurological disease or condition;
determining, based on the first patient data, first seizure data and first side effect data during the baseline time period;
receiving, from the one or more patient monitoring devices, second patient data for a treatment time period in which the patient is taking the medication;
determining, based on the second patient data, second seizure data and second side effect data during the treatment time period;
generating and outputting a visualization of a personalized dose-response profile for the patient, wherein the visualization of the personalized dose-response profile comprises: (1) a visual representation of a therapeutic profile representing a relationship between seizure control and different dosages of the medication determined based on the first and second seizure data, and (2) a visual representation of a toxicity profile representing a relationship between side effect severity and the different dosages of the medication determined based on the first and second side effect data; and
outputting a treatment recommendation for the patient, wherein the treatment recommendation comprises administering a dose of the medication to the patient to treat the neurological disease or condition, and wherein the dosage is selected based on the personalized dose-response profile.

### Claim 2 (depends on 1)

The computer-implemented method of claim 1, wherein the neurological disease or condition comprises epilepsy or a disorder having epilepsy as a symptom.

### Claim 3 (depends on 1)

The computer-implemented method of claim 1, wherein the one or more patient monitoring devices comprise an eye tracking device.

### Claim 4 (depends on 1)

The computer-implemented method of claim 1, wherein the eye movement data includes one or more of the following: blink rate, blink duration, eye eccentricity, eye gaze angle, pupil size, pupil constriction amount, pupil constriction velocity, pupil dilation amount, pupil dilation velocity, pupil location, pupil rotation, pupil area to iris area ratio, hippus, eyelid movement rate, eyelid openings, eyelid closures, eyelid height, upward eyeball movements, downward eyeball movements, lateral eyeball movements, eye rolling, jerky eye movements, saccadic velocity, saccadic direction, torsional velocity, torsional direction, gaze direction, gaze scanning patterns, or eye activity during sleep.

### Claim 5 (depends on 1)

The computer-implemented method of claim 1, wherein the one or more patient monitoring devices comprise one or more of the following: a facial tracking device, a brain monitoring device, a mobile device, an implantable device, a wearable device, or a computing device.

### Claim 6 (depends on 1)

The computer-implemented method of claim 1, wherein the first and second seizure data include data representing one or more of a type, a timing, an ictal duration, a postictal duration, a frequency, a severity, or a variability of at least one seizure event experienced by the patient.

### Claim 7 (depends on 6)

The computer-implemented method of claim 6, wherein the at least one seizure event comprises one or more of the following: an absence seizure, an atypical absence seizure, a tonic-clonic seizure, a clonic seizure, a tonic seizure, an atonic seizure, a myoclonic seizure, a simple partial seizure, a complex partial seizure, a secondary generalized seizure, or an infantile spasm.

### Claim 8 (depends on 1)

The computer-implemented method of claim 1, further comprising comparing the first and second seizure data to determine a change in seizure burden between the baseline time period and the treatment time period.

### Claim 9 (depends on 1)

The computer-implemented method of claim 1, wherein the first and second side effect data include data representing one or more of a type, a timing, a duration, a frequency, or a severity of at least one side effect experienced by the patient.

### Claim 10 (depends on 9)

The computer-implemented method of claim 9, wherein the at least one side effect comprises one or more of the following: drowsiness, a decrease in cognition, a decrease in attention, a decrease in concentration, a change in mood, a change in behavior, a change in memory loss of consciousness, suicidality, homicidality, irritability, or a change in vision.

### Claim 11 (depends on 1)

The computer-implemented method of claim 1, further comprising comparing the first and second side effect data to determine a change in side effect severity between the baseline time period and the treatment time period.

### Claim 12

A computer-implemented method for managing epilepsy, the method comprising:
receiving, from an eye tracking device, first eye movement data of a patient during a baseline period before the patient has started taking a medication for the epilepsy;
determining, based on the first eye movement data, first seizure burden data and first neurocognitive data for the patient during the baseline period;
receiving, from the eye tracking device, second eye movement data of the patient during a treatment period in which the patient is taking the medication;
determining, based on the second eye movement data, second seizure burden data and second neurocognitive data for the patient during the treatment period;
generating and outputting a visualization of a personalized dose-response profile for the patient, wherein the visualization of the personalized dose-response profile comprises: (1) a visual representation of a therapeutic profile representing a relationship between seizure control and different dosages of the medication determined based on the first and second seizure burden data, and (2) a visual representation of a toxicity profile representing a relationship between neurocognitive state and the different dosages of the medication determined based on the first and second neurocognitive data; and
outputting a treatment recommendation for the patient, wherein the treatment recommendation comprises administering a dosage of the medication to the patient to treat the epilepsy, and wherein the dosage is selected based on the personalized dose-response profile.

### Claim 13 (depends on 12)

The computer-implemented method of claim 12, wherein:
the first and second seizure burden data are determined from the first and second eye movement data using a first set of algorithms, and
the first and second neurocognitive data are determined from the first and second eye movement data using a second set of algorithms.

### Claim 14 (depends on 13)

The computer-implemented method of claim 13, wherein the first set of algorithms includes at least one machine learning algorithm trained on seizure data from a plurality of patients, and the second set of algorithms includes at least one machine learning algorithm trained on interictal data from a plurality of patients.

### Claim 15 (depends on 12)

The computer-implemented method of claim 12, further comprising:
receiving, from the eye tracking device, third eye movement data for a subsequent treatment period during which the patient is taking a different dosage of the medication, and
determining, based on the third eye movement data, third seizure burden data and third neurocognitive data during the subsequent treatment period,
wherein the personalized dose-response profile for the patient is generated based on the third seizure burden data and the third neurocognitive data.

### Claim 16 (depends on 12)

The computer-implemented method of claim 12, further comprising receiving additional patient data, wherein one or more of the first seizure burden data, first neurocognitive data, second seizure burden data, or second neurocognitive data are determined based on the additional patient data, and wherein the additional patient data is received from one or more of the following: a facial tracking device, a brain monitoring device, a mobile device, an implantable device, a wearable device, or a computing device.

### Claim 17 (depends on 12)

The computer-implemented method of claim 12, wherein the treatment recommendation is determined using a machine learning algorithm trained on dose-response profiles from a plurality of patients.

### Claim 18 (depends on 12)

The computer-implemented method of claim 12, wherein the first and second neurocognitive data include data representing one or more of a type, a timing, a duration, a frequency, or a severity of at least one change to the patient's attention, mood, or memory.

### Claim 19 (depends on 12)

The computer-implemented method of claim 12, wherein the eye tracking device comprises a camera of a mobile device.

### Claim 20 (depends on 12)

The computer-implemented method of claim 12, wherein the visualization of the personalized dose-response profile further comprises a visual representation of a natural history curve indicating changes to the patient's baseline neurocognitive state.